Retatrutide Research
Phase 3 trials, FDA timeline, and scientific evidence behind the next generation of weight loss drugs.
FDA Approval Status (February 2026)
Phase 3 results, submission timeline, and expected 2027-2028 launch window explained.
Complete 2026-2028 Roadmap
When Eli Lilly will submit, how long FDA review takes, and realistic availability dates.
Retatrutide vs Tirzepatide
24% vs 22% weight loss—see the trial data comparing the two drugs side by side.
How Retatrutide Works
Triple-agonist mechanism explained: GLP-1, GIP, and glucagon receptor activation.
Dosing Guide & Titration
Phase 3 protocol: starting doses, escalation schedule, and maximum effective dose (12mg).
Side Effects & Safety Guide
Clinical trial safety data: nausea rates, dysesthesia risk, heart effects, and warnings.
Knee Pain & Osteoarthritis
TRIUMPH-4 trial: how retatrutide reduced knee pain in patients with osteoarthritis.
Fatty Liver: 80% Reduction
Breakthrough results in non-alcoholic fatty liver disease (NASH) clinical trials.
Dysesthesia & Heart Rate
What is dysesthesia? Why does it happen? Plus heart rate increases explained.
Want to Stay Updated?
We monitor Phase 3 trials, FDA submissions, and research publications so you don't have to. Join the waitlist for updates.
Get Research Updates
Be notified when new trial data, FDA decisions, or launch dates are announced.